RT Journal Article
SR Electronic
T1 Sulfated N-glycans Upregulation in Sera Predicts Early-Stage Breast Cancer in Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.27.24305000
DO 10.1101/2024.03.27.24305000
A1 Feleke, Dereje G.
A1 Montalban, Bryan M.
A1 Gizaw, Solomon T.
A1 Hinou, Hiroshi
YR 2024
UL http://medrxiv.org/content/early/2024/03/28/2024.03.27.24305000.abstract
AB Alterations in sulfated glycans are associated with several pathological conditions, including cancer. However, analysis of sulfated glycans poses challenges, making the investigation of sulfated glycan profiles a topic of significant interest in the search for novel biomarkers for early BC detection. We used a glycoblotting-based sulphoglycomics workflow to examine sulfated N-glycans present in the serum of Ethiopian patients with BC. Seven mono-sulfated glycans were significantly upregulated in the sera of BC patients compared to the control group. Each identified glycan showed significant abundance with AUC ≥ 0.8 and demonstrated high diagnostic accuracy in predicting early stage BC patients. Importantly, the sulfated glycans were analyzed without removing the sialic group, allowing for comprehensive evaluation of the sialylation status of the identified sulfated glycans. This study represents the first quantitative analysis of sulfated N-glycans in patients with BC and identifies novel biomarkers with discriminatory potential in the early stages of BC.Statement of significance This study presents a quantitative analysis of sulfated N-glycans in BC, aiming to identify novel glyco-biomarkers that demonstrate high diagnostic accuracy for early stage BC. Analyzing sulfated glycans without removing sialic acids offers comprehensive insights. These findings advance the understanding of BC, potentially enhance early detection, and improve patient outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS. Tebeje reports grant from Addis Ababa University for Breast Cancer Thematic Research. H. Hinou reports grants from JSPS KAKENHI and Core-to-Core B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from all study participants and the study was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki. The ethical review boards of Addis Ababa University, School of Medicine, Ethiopia, and Hokkaido University, Faculty of Advanced Life Sciences, Japan approved the research protocols.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available in the main text or supplementary materials.